Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31550151 | 0.84 | PARP1 (0.42) | PARP1VCPRXRAGRIN1GRIN2B | |
| SCHEMBL8243510 | 0.84 | PARP1 (0.42) | PARP1VCPRXRAGRIN1GRIN2B | |
| SCHEMBL21831869 | 0.83 | KDM1A (0.36) | PARP1ADRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30910946 | 0.83 | KDM1A (0.36) | PARP1ADRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30726196 | 0.82 | PARP1 (0.40) | PARP1PFKFB3VCPRXRAGRIN1 | |
| SCHEMBL30846954 | 0.82 | CES2 (0.41) | CYP1A2CYP2C9CYP2C19SHBGADRA2B | |
| SCHEMBL248016 | 0.82 | PARP1 (0.40) | PARP1PFKFB3VCPRXRAGRIN1 | |
| SCHEMBL11213329 | 0.82 | PARP1 (0.37) | PARP1VCPCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3518451 | 0.82 | CES2 (0.41) | CYP1A2CYP2C9CYP2C19SHBGADRA2B | |
| SCHEMBL3864260 | 0.82 | PARP1 (0.39) | PARP1PFKFB3VCPRXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9283222-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| CN-103492361-B | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof | BAYER IP GMBH | 2015-07-15 | — | — | CN | disclosed |
| EP-2698062-B1 | Inhibitors of poly(adp-ribose)polymerase | ABBVIE INC (US) | 2015-06-24 | — | — | EP | disclosed |
| CN-104470895-A | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | Bayer Pharma AG | 2015-03-25 | — | — | CN | disclosed |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2698062-A1 | Inhibitors of poly(adp-ribose)polymerase | Abbvie Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2120579-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8466150-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2013-06-18 | — | — | US | disclosed |
| EP-2120579-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008083027-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | PARP1, DPYD, PARP2 | PARP1 1/4885PFKFB3 1676/4885VCP 3482/4885 |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | PARP1 1/4885PFKFB3 3945/4885VCP 1789/4885 |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | PARP1 1/4885PFKFB3 3945/4885VCP 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.